Literature DB >> 11911988

The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans.

Rüdiger Hilker1, Christine Klein, Katja Hedrich, Laurie J Ozelius, Peter Vieregge, Karl Herholz, Peter P Pramstaller, Wolf Dieter Heiss.   

Abstract

Autosomal recessive parkinsonism associated with mutations in the parkin gene represents a monogenic form of hereditary parkinsonism. We performed [(18)F]6-fluorodopa (FDOPA) positron emission tomography as a measurement of the nigrostriatal dopaminergic system as well as extensive haplotype analysis of the PARK 2 gene locus in 14 subjects with parkin mutations. In parkin subjects, the reduction of striatal FDOPA uptake increased with the number of mutated alleles and was also slightly obvious in asymptomatic parkin gene carriers in the heterozygous state. The abnormal FDOPA uptake pattern in parkin patients did not significantly differ from that of sporadic Parkinson's disease. Our data are in agreement with an enzymatic dysfunction of the gene's translational product, which has been shown to promote protein degradation as an ubiquitin-protein ligase. Thus, parkinsonism in parkin gene carriers may be related to abnormal nigral protein accumulation in the presence of a suprathreshold enzyme dysfunction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11911988     DOI: 10.1016/s0304-3940(01)02529-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  16 in total

1.  The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.

Authors:  Madeleine E Sharp; Elise Caccappolo; Helen Mejia-Santana; Ming-X Tang; Llency Rosado; Martha Orbe Reilly; Diana Ruiz; Elan D Louis; Cynthia Comella; Martha Nance; Susan Bressman; William K Scott; Caroline Tanner; Cheryl Waters; Stanley Fahn; Lucien Cote; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Haydeh Payami; Eric Molho; Stuart A Factor; John Nutt; Carmen Serrano; Maritza Arroyo; Michael W Pauciulo; William C Nichols; Lorraine N Clark; Roy N Alcalay; Karen S Marder
Journal:  Mov Disord       Date:  2014-11-12       Impact factor: 10.338

Review 2.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

3.  Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities.

Authors:  Cheng Wang; Ruifeng Lu; Xuezhi Ouyang; Michelle W L Ho; William Chia; Fengwei Yu; Kah-Leong Lim
Journal:  J Neurosci       Date:  2007-08-08       Impact factor: 6.167

Review 4.  Twenty years since the discovery of the parkin gene.

Authors:  Nobutaka Hattori; Yoshikuni Mizuno
Journal:  J Neural Transm (Vienna)       Date:  2017-06-15       Impact factor: 3.575

Review 5.  [Nuclear medicine imaging in patients with Parkinson's syndrome: an update].

Authors:  J Schwarz
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

6.  Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.

Authors:  L N Clark; B M Ross; Y Wang; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder
Journal:  Neurology       Date:  2007-09-18       Impact factor: 9.910

7.  Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available cases and control.

Authors:  J Brooks; J Ding; J Simon-Sanchez; C Paisan-Ruiz; A B Singleton; S W Scholz
Journal:  J Med Genet       Date:  2009-04-06       Impact factor: 6.318

Review 8.  Genetics of parkin-linked disease.

Authors:  Andrew B West; Nigel T Maidment
Journal:  Hum Genet       Date:  2004-01-15       Impact factor: 4.132

Review 9.  PET-based molecular imaging in neuroscience.

Authors:  A H Jacobs; H Li; A Winkeler; R Hilker; C Knoess; A Rüger; N Galldiks; B Schaller; J Sobesky; L Kracht; P Monfared; M Klein; S Vollmar; B Bauer; R Wagner; R Graf; K Wienhard; K Herholz; W D Heiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-23       Impact factor: 9.236

10.  Substantia nigra hyperechogenicity in healthy controls: a [¹⁸Fluoro] Dopa-PET follow-up study.

Authors:  Ute Schroeder; Stefanie Behnke; Hans-Georg Buchholz; Klaus Fassbender; Matthias Schreckenberger; Daniela Berg
Journal:  J Neurol       Date:  2013-04-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.